Notably, we observed an increasing trend in AE since 2019, suggesting both expanded clinical use and heightened pharmacovigilance awareness.
← all excerpts
Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data.
1
—
—
Notably, we observed an increasing trend in AE since 2019, suggesting both expanded clinical use and heightened pharmacovigilance awareness.